Dongling Su
19Patents
7h-index
17Co-inventors
59Inventor score
Filing activity: Jun 25, 2004 → Jul 10, 2018
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7956028B2 | Protein stabilization formulations | Human Necessities | 17 | Active |
| US8398611B2 | Compositions and methods for treating joints | Human Necessities | 15 | Active |
| US8524662B2 | Compositions and methods for treating joints | Human Necessities | 10 | Active |
| US8455436B2 | Compositions and methods for treating joints | Human Necessities | 8 | Active |
| US7947649B2 | Liquid buffered GDF-5 formulations | Human Necessities | 8 | Active |
| US7678764B2 | Protein formulations for use at elevated temperatures | Human Necessities | 7 | Active |
| US8623839B2 | Compositions and methods for stabilized polysaccharide formulations | Human Necessities | 7 | Active |
| US7964561B2 | Protein formulations for use at elevated temperatures | Human Necessities | 7 | Active |
| US8815284B2 | Bioerodible sustained release drug delivery systems | Human Necessities | 5 | Active |
| US8435943B2 | Protein stabilization formulations | Human Necessities | 5 | Active |
| US8895506B2 | Protein stabilization formulations | Human Necessities | 5 | Active |
| US9682099B2 | Compositions and methods for treating joints | Human Necessities | 2 | Active |
| US9561260B2 | Compositions for treating joints comprising bone morphogenetic protein and hyaluronic acid | Human Necessities | 0 | Active |
| US11090328B2 | Compositions and methods for treating joints | Human Necessities | 0 | Active |
| US10300114B2 | Bioerodible sustained release drug delivery systems | Human Necessities | 0 | Active |
| US8927491B2 | Methods for forming compositions for treating joints comprising bone morphogenetic protein and hyaluronic acid | Human Necessities | 0 | Active |
| US10532069B2 | Compositions and methods for treating joints | Human Necessities | 0 | Active |
| US8058237B2 | Stable composition of GDF-5 and method of storage | Human Necessities | 0 | Active |
| US9566336B2 | In situ gelling drug delivery system | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.